Migsun (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredients in Migsun, are an NSAID and a selective 5‑HT1B/1D receptor agonist presented as an oral tablet for the acute treatment of migraine attacks in adults. The combination provides anti‑inflammatory pain relief together with cranial vasoconstriction to alleviate migraine symptoms.

GNH USA supplies Migsun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and regulatory compliance for global distribution, with reliable logistics, post‑market support, and technical assistance.

Migsun combines an NSAID and a triptan to target migraine pathophysiology.

- Migraine attack: rapid relief of headache pain and associated symptoms. - Migraine with aura: reduction of headache intensity and associated neurological symptoms. - Acute episodic migraine: prevention of progression to severe pain when taken early.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Fatigue: feeling of tiredness. - Abdominal pain: discomfort in the stomach area. - Tingling sensation: paresthesia in extremities.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe allergic reaction: rash, swelling, anaphylaxis. - Cardiovascular events: stroke or myocardial infarction. - Severe hypertension: sudden rise in blood pressure. - Hepatic dysfunction: elevated liver enzymes.

Before prescribing Migsun, consider the following precautions: - Cardiovascular assessment: evaluate risk of ischemic heart disease. - Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy. - Serotonin syndrome monitoring: watch for signs when combined with serotonergic agents. - Renal or hepatic impairment: adjust use based on organ function. - Uncontrolled hypertension: contraindicated in severe high blood pressure. - Store at room temperature: keep in the original pack, protect from moisture.

Migsun may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans: additive vasoconstriction leading to cardiovascular events. - SSRIs/SNRIs: increased risk of serotonin syndrome. - Anticoagulants/antiplatelet agents: heightened bleeding risk from naproxen. - CYP2D6 inhibitors: may raise sumatriptan plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood pressure control. - Diuretics: may affect electrolyte balance. - Additional NSAIDs: increased gastrointestinal toxicity. - Oral contraceptives: potential for reduced efficacy. - Lithium: enhanced lithium toxicity risk.